Tricia Kunst

Papers

Total Citations

H-Index

About

Tricia Kunst is a cancer researcher whose work focuses on precision medicine for esophageal cancers, particularly through innovative metabolic and apoptotic profiling techniques. Her most cited study, "Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy" (2018, 8 citations), addresses a critical challenge in oncology: predicting which patients will benefit from neoadjuvant chemoradiotherapy (nCRT) before esophagectomy. By integrating metabolomics—analyzing small-molecule metabolites in tumors—with BH3 profiling, which measures a cell’s readiness to undergo apoptosis, Kunst developed a dual-assay approach that could identify patients likely to achieve a pathological complete response. This work is significant because esophageal cancer remains highly lethal, with nearly 16,000 deaths annually in the U.S., and current treatment protocols often expose patients to toxic therapies without clear benefit. Kunst’s contributions offer a pathway toward more personalized, less invasive treatment decisions, potentially sparing non-responders from unnecessary side effects. Her research exemplifies the growing intersection of functional diagnostics and precision oncology, and though early in her career, her 2018 paper has already shaped discussions on biomarker-driven therapy in gastrointestinal malignancies.